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Abstract 
Research into biomarkers of periodontitis is driven by mainly three targets: to identify “at 
risk” patients before periodontal tissue destruction occurs, to determine disease activity 
and progression, and to build up our understanding of this complex disease with the 
purpose of finding new therapeutic targets.  Whilst previously blood and gingival crevicular 
fluid were the biological samples of choice, recently saliva has gained more attention as a 
readily accessible oral fluid and which has a mediator profile similar to that of serum and 
gingival crevicular fluid. The aim of this paper is to give a comprehensive overview of 
salivary cytokines in periodontitis, highlighting extensively studied cytokines such as 
interleukin-1β and interleukin-6, but also cytokines which only have been the subject of few 
studies and which warrant further investigation.  Cross-sectional and longitudinal studies of 
salivary cytokines and the potential of cytokines as periodontitis biomarkers are evaluated. 
Finally, a discussion of potential confounding factors such as concurrent systemic diseases 
and smoking is presented.  
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Periodontal disease is time consuming and expensive to treat and therefore its prevention, 
early detection and management are issues which, if effectively addressed, are likely to yield 
considerable healthcare benefit [97].  However, despite numerous advances in our 
understanding of the pathogenesis of chronic inflammatory diseases, periodontitis is still 
only diagnosed once connective tissue and bone destruction has occurred.  Furthermore, 
monitoring disease progression is a highly skilled and technically demanding process 
involving measurement of bleeding on probing, probing depth and attachment loss coupled 
with radiographic assessment and (subjective) visual observations [76]. The development of 
biomarkers for early detection of periodontal disease and to identify progression would be 
highly desirable as current diagnostic approaches do not reflect current disease activity, but 
simply assess the cumulative effects of historical tissue destruction  [53].  Rational diagnosis 
would also have concomitant patient benefit as the paucity of evidence-based knowledge of 
disease progression in individual patients may lead to unintentional clinical mismanagement 
[97]. In addition, studies of the salivary mediators associated with disease may help in the 
development of novel therapies aimed at controlling cytokine bioavailability (e.g. through 
anti-cytokine antibodies, antagonists or soluble receptors) or targeting the intra-cellular 
signalling pathways they activate, approaches which have been successful in the treatment 
of other chronic inflammatory diseases such as rheumatoid arthritis [60, 91, 95].  
Cytokines have been defined as soluble factors produced by one (immune) cell that 
act on another cell within the same milieu [26] . However, it is now recognised that the 
range of molecules with cytokine-like activity can be extended to include, for example 
growth factors and adipokines which also have immunoregulatory functions. Importantly, 
cytokine functions often overlap or merge, building a complex immunoregulatory network 
in the immune system that is often perturbed in disease.  It is increasingly appreciated that 
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cytokines have vital roles in the development and homeostasis of numerous cell types and, 
in a wide range of tissues, have roles in resolution of inflammation, wound healing, repair 
and regeneration. In the following review, the term “cytokine” will be used in this broad 
context. In addition to direct analysis of cytokines, the levels of molecules such as matrix 
metalloproteinases and tissue inhibitors of metalloproteinases which are regulated by 
cytokines have also been given considerable attention as potential periodontitis biomarkers, 
as reviewed elsewhere in this issue. 
 
Cytokines and periodontal diseases 
It is now widely accepted that although the initiating factors in gingivitis and periodontitis 
are the microbial elements of the dental plaque biofilm, the pathogenesis and concomitant 
tissue destruction is driven by the development of a chronic, inflammatory host immune 
response, the nature and extent of which are fundamental determinants of susceptibility 
and progression.  The function of immune cells and periodontal tissue cells in orchestrating 
periodontal disease pathogenesis is underpinned by the functional diversity of cytokines 
[56, 79]. The earliest cytokine studies in periodontal research can be dated back to the 
1980s [20, 62] and coincide with the detailed characterisation of interleukin-1, interleukin-2 
and tumor necrosis factor- [26]. These experiments showed increased thymocyte 
proliferation induced by gingival crevicular fluid from inflamed sites compared to non-
inflamed sites, which was presumed to be due to cytokine-like activity, although the precise 
molecular nature of the mediators remained to be determined [20, 62]. With the 
establishment of enzyme-linked immunosorbant assays, interleukin-1 β was the first 
cytokine to be specifically measured in the gingival tissue of patients with periodontal 
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disease [44]; since then, many publications have reported the measurement of cytokines in 
periodontal tissues, periodontal cell culture supernatants and oral fluids  [17, 56, 79, 102].  
While early studies focused on serum and gingival crevicular fluid samples for 
investigations of periodontitis-related cytokines, saliva has come into focus as an alternative 
source of biomarkers in recent years [17, 102, 115]. Saliva is made up of the exocrine 
secretions of the salivary glands in addition to gingival crevicular fluid, microbial 
components and food remnants [10, 38]. Analysis of saliva, similar to gingival crevicular 
fluid, gives a better representation of the local pathological changes in the mouth than 
analysis of serum. However, saliva has several advantages over gingival crevicular fluid, as it 
is more easily accessible than gingival crevicular fluid, can be sampled in a much larger 
volume without the need for clinical facilities and there are no complex skills necessary for 
saliva sampling.  Furthermore, whereas gingival crevicular fluid content reflects 
inflammatory processes at individual disease sites, it is reasonable to suggest that saliva 
content reflects a consensus ‘whole of mouth’ inflammatory status, which is likely to be 
much more clinically relevant.   
The “Biomarkers Definitions Working Group” defines a biomarker as: “A characteristic that 
is objectively measured and evaluated as an indicator of normal biological processes, 
pathogenic processes, or pharmacologic responses to a therapeutic intervention” [12]. 
Individual biomarkers should be discriminatory and robust (see below). Also, the utility of a 
biomarker needs to be assessed using appropriate study design and methodology [57]. Most 
studies are simply designed to be cross-sectional, comparing the levels of cytokines in 
groups of healthy volunteers and periodontal disease patients. Superficially, such studies 
merely report associations of biomarkers with the presence of disease and therefore test 
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whether or not a particular marker is discriminatory. Many, but not by any means all, 
studies attempt statistical correlation with clinical parameters of periodontitis such as 
clinical attachment loss and probing depth; this approach is weakened by the knowledge 
that these parameters may merely reflect historical disease activity rather than 
contemporary processes.  Cross-sectional studies do not indicate whether or not a particular 
salivary biomarker mirrors disease progression and/or response to treatment. Studies of 
longitudinal changes in salivary biomarkers to date have been rather limited and have used 
highly variable clinical protocols [17, 102]. Although these studies help identify candidate 
disease markers and many have replicated data derived from studies of gingival crevicular 
fluid, the majority of studies relate to a limited number of popular biomarkers and a 
significant number of studies have not been reproduced independently, at least using 
comparable methodologies [102].  It has also been noted that many clinical research studies 
of periodontal disease fail to report examiner calibrating procedures for the measurement 
of parameters such as probing depth, attachment loss or bleeding on probing [42]. The lack 
of uniformity in periodontitis definitions is another factor that makes comparisons of 
different studies challenging [78]. Another potential flaw in study design is the quality of the 
methodology to assess cytokine concentrations in saliva. Enzyme-linked immunosorbant 
assays clearly have the advantage in terms of high throughput and high reproducibility. 
Most research studies use commercially available enzyme-linked immunosorbant assays kits 
for sample analysis, however the efficacy of these kits in measuring mediators in saliva has 
not been reported in any study; most assays have been optimised by the manufacturers for 
use with serum samples. Failing to validate an enzyme-linked immunosorbant assay for its 
suitability for use with saliva samples can lead to erroneous results and could partly explain 
inconsistencies in findings between different studies; for example we have noted same 
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assays exhibit poor sample recovery from saliva and poor inter-assay variation for 
measurement of salivary mediators [47].  Similar data have been reported in a study 
comparing the performance of multiplex cytokines assays although recovery can, in some 
cases, be improved by sample pre-treatment [15]. 
Concerns regarding the widespread adoption of inappropriate statistical approaches 
in biomedical research have been raised in the literature [30, 72]. Our review of the 
literature on cytokine biomarkers for periodontal disease (see tables) revealed that whilst 
the majority of studies apply correct statistical analysis procedures, there remain not 
infrequent examples of statistical errors: e.g. the use of parametric tests (e.g. t-tests) when 
data are not parametric; the use of dependent samples tests when data are independent 
(for example paired samples t-tests instead of independent samples t-test); inappropriately 
using a mixture of parametric and non-parametric tests (for example, performing an analysis 
of variance followed by Mann-Whitney-U comparisons). In addition, few studies report a 
formal power calculation for sample size and likely many of the reviewed studies are 
underpowered. Furthermore, although most studies did take normal distribution of their 
sample groups into account, many used the Kolmogorov–Smirnov test to assess normal 
distribution and only a minority of studies used the Shapiro-Wilk test. This is of concern as 
the Kolmogorov–Smirnov test is valid for a sample sizes of n>2000 whereas the Shapiro-Wilk 
test of normal distributions is valid for a smaller sample sizes and has superior statistical 
power [83]. Some studies have reported data from receiver-operator characteristic analysis 
[29, 80]  which establishes the efficacy of biomarker analysis in identifying individuals in an 
unselected population sample with or without a particular condition such as periodontitis by 
comparing sensitivity and specificity of a particular technique [112].  The value of receiver-
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operator characteristic statistics clearly depends on the application of the biomarker 
analysis: it has value to confirm the robustness of an approach to identifying disease (e.g. 
for use by untrained workers in the field) but does not indicate whether the test outcome is 
relevant for disease progression which is of greater interest in disease management. Clearly, 
much remains to be done to improve study designs, analysis, and reporting in studies of 
biomarkers levels in periodontal diseases. 
Salivary cytokines in oral health and periodontal disease 
Interleukin-1 family  
The interleukin-1 family of cytokines is defined on the basis of structural similarity and 
comprises 11 members, further divided into 3 sub-families: the interleukin-1 sub-family 
(interleukin-1, interleukin-1  interleukin  ), 
the interleukin-18 sub-family (interleukin-18, interleukin-37) and the interleukin-36 sub-
family (interleukin-36, interleukin-36  interleukin   interleukin  
interleukin-36 receptor antagonist) [36, 109]. The interleukin-1 cytokines are produced by a 
wide variety of cell types and perform critical functions in innate and adaptive immune 
responses to infection  [36, 109]. In terms of pathogenesis, the interleukin-1 cytokines are 
generally pro-inflammatory but and interleukin-36Ra have 
antagonistic functions [36, 109].  
Interleukin-1β is the prototypical interleukin-1 cytokine and as such is the most 
extensively studied cytokine in clinical studies of salivary biomarker in periodontal disease. 
Interleukin-1β has a multitude of immunological functions including activation of 
neutrophils, T-and B-cells during infection as well as mediating liver acute phase protein 
release and febrile responses (reviewed in [27]). In periodontitis, interleukin 1β is associated 
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with neutrophil recruitment and activation of osteoclasts through its ability to induce 
chemokines and activate osteoclasts [79]. Furthermore, the association between 
periodontitis and elevated interleukin-1β in gingival crevicular fluid is well established [7, 
17].  In case control studies, 9 out of the 12 studies show a significantly higher interleukin-
1β level in periodontitis compared to healthy controls (Table 1). In other studies (n=3), 
interleukin-1β levels are significantly correlated with clinical parameters of periodontitis 
(Table 1). In addition, there are consistent findings from 3 independent studies that levels of 
salivary interleukin-1β decrease after periodontal treatment (Table 1). Interleukin-1β 
concentrations in saliva are not affected by systemic conditions such as diabetes or smoking 
(see below). The potential of salivary interleukin-1β to discriminate between periodontal 
health and disease with high specificity and sensitivity in receiver operator curve analysis 
has been investigated but with conflicting results [29, 80]. It is noteworthy that there is 
considerable variation in the levels of salivary interleukin-1β reported; levels in health range 
from an average of 7.24 ± 7.69 pg/ml [29] to as much as 633.91 ± 91.0 pg/ml [103] and 
levels in periodontitis patients range from an average of 90.94 ± 85.22 pg/ml [29] to 1312 ± 
691.22 pg/ml [50].  Notwithstanding differences in patient selection criteria, these findings 
make precise comparisons between studies challenging. Thus, it would seem there is 
substantial but not unanimous support for the notion that salivary interleukin-1β is a robust 
choice of analyte for studies of periodontal disease biomarkers. 
Only a limited number of studies have investigated salivary concentrations of other 
members of the interleukin-1 family of cytokines in periodontitis. Interleukin-1 has been 
detected in saliva but the levels are not altered in periodontitis [31]. Although interleukin-1 
receptor anatagonist has well-defined antagonist roles in immunoregulation [36, 109], there 
are currently no reports of the investigation of salivary interleukin-1 receptor anatagonist in 
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periodontitis. Interleukin-18 is secreted by a number of cell types (myeloid cells, 
keratinocytes, epithelial cells) and by activating neutrophils and Th1 cells potentially plays 
an important role in periodontal inflammation (reviewed in [7]). Increased concentrations of 
interleukin-18 were found in the saliva of periodontitis patients compared to healthy 
controls [74].  Salivary concentrations of interleukin-33, an interleukin-1 family member that 
drives Th2 cytokine responses, appear to remain unaffected by periodontitis [18] (Table 1). 
Although the role of other, newly identified members of the interleukin-1 family in chronic 
inflammatory diseases is receiving increasing attention [79] nothing is known about salivary 
concentrations of these novel cytokines.  
Tumor necrosis factor-α  
The tumor necrosis factor-α superfamily comprises some 19 ligands identified on the basis 
of gene sequence homology [1]. A survey of the various physiological roles of these ligands 
reveals wide-ranging roles in cell proliferation, apoptosis and morphogenesis as well as host 
immune defence [1]. However, with the exception of tumour necrosis factor-α and receptor 
activator of nuclear factor kappa-B ligand (see below) there is little or no information about 
the potential of the tumour necrosis factor superfamily members as biomarkers of 
periodontitis. Tumor necrosis factor-α is a key pro-inflammatory cytokine and central to 
anti-microbial immunity at a number of levels.  The fundamental physiological role of this 
cytokine beyond the immune system is now established and tumor necrosis factor-α has 
numerous homeostatic functions in human physiology including a role in neurological 
regulation [91]. Tumor necrosis factor-α is produced mainly by macrophages as a primary 
response of Toll-like receptor signalling, by activated T cells and NK cells and also by non-
immune cells including endothelial cells and fibroblasts [91]. The long-standing success of 
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anti- tumor necrosis factor-α therapy in rheumatoid arthritis has heightened interest in this 
important cytokine in inflammatory diseases such as periodontitis.  
Tumor necrosis factor-α and receptor activator of nuclear factor kappa-B ligand both 
belong to the tumour necrosis factor superfamily, and both are potent activators of 
osteoclasts and thereby mediate bone resorption [39]. Some 7 studies have investigated 
salivary tumour necrosis factor-α in periodontal health and disease (Table 2) however, 
tumor necrosis factor-α is either undetectable or the levels detected in saliva are very low.  
Frodge et al [33] reported significantly higher salivary tumour necrosis factor-α 
concentrations in periodontitis compared to periodontal health using a highly sensitive 
detection methodology, but the levels detected in the different patient groups were 
nonetheless very low (<4.3pg/ml). Although after periodontal treatment salivary tumor 
necrosis factor- α concentrations were reported to decrease [92] there is no evidence that 
salivary tumour necrosis factor- α levels correlate with clinical changes in the periodontium 
either during disease progression [89] or after treatment [92]. Currently, therefore, it seems 
unlikely that salivary tumor necrosis factor-α can be regarded as a good candidate 
biomarker for periodontal disease. 
Interleukin-6 
Interleukin-6 is produced by innate immune cells such as macrophages and dendritic cells 
but also by some CD4+ T-cells as well as non-immune cells such as fibroblasts and 
endothelial cells [84]. Interleukin-6 is elevated in many inflammatory diseases and mainly 
functions to activate B-lymphocytes in addition to having a role in influencing the balance of 
CD4+ effector T-cell populations and potentially influencing myeloid cell differentiation [84].  
Interest in interleukin-6 has recently increased as anti-interleukin-6 blockade has proven to 
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be efficacious in the treatment of rheumatoid arthritis [48, 84]. Levels of interleukin-6 
measured in saliva are low in both periodontal health and disease [29]. Also, while some 
studies have shown that salivary interleukin-6 concentrations are significantly higher in 
periodontitis than in healthy individuals, others found no differences between the two 
groups (Table 2). Reports on post-treatment evaluations of salivary interleukin-6 
concentrations showed no significant changes [54, 77]. Therefore, interleukin-6 is not a 
robust salivary periodontitis biomarker.  Interleukin-6 is a member of a family of cytokines 
which have overlapping biological functions and binding receptors which share a common 
subunit (gp130); these include leukaemia inhibitory factor, interleukin-11 and oncostatin M 
[84] although these mediators are yet to be assessed as potential salivary biomarkers for 
periodontal disease. 
Interleukin-4 
Interleukin-4 is mainly produced by T-cells, specifically the Th2 subset of T-cells and has 
important functions in the regulation of cell proliferation and apoptosis in numerous cell 
types, including lymphocytes, myeloid cells, fibroblasts and epithelial cells [59]. Interleukin-4 
is a critical mediator in regulating T-cell development and plasticity in periodontal disease 
[32]. However, interleukin-4 is only present at very low concentrations in saliva and findings 
relating to salivary concentrations of interleukin-4 in periodontitis are inconsistent: one 
study reported significantly higher interleukin-4 concentrations in periodontitis [77] and two 
studies find no differences in salivary interleukin-4 concentrations between periodontal 
health and disease [80, 103]. Similarly, although one study reported a treatment-related 
reduction in salivary interleukin-4 levels [77], other studies do not report any evidence for 
post-treatment changes in salivary interleukin-4 in periodontitis patients [31, 89]. Therefore 
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interleukin-4 cannot, as yet, be considered a viable salivary biomarker for periodontal 
disease.  
Interleukin-10 
The interleukin-10 family of cytokines has some nine members of which interleukin-10 itself 
is the most studied [73, 88]. Interleukin-10 is widely produced by innate and adaptive 
immune cells alike and is a key anti-inflammatory cytokine, involved in inhibiting and 
regulating pro-inflammatory immune responses and promoting resolution of inflammation 
[73]. However, data from clinical studies have been inconsistent (Table 2): one study 
reported significantly lower levels in periodontitis compared to controls [77] and others 
have  found no differences in salivary interleukin-10 concentrations between periodontal 
health and disease [80, 103] (Table 2). Periodontal treatment does not appear to affect 
salivary interleukin-10 concentrations [54, 77] and initial levels do not correlate with disease 
progression [89]. Thus, evidence from clinical studies does not support the notion that 
interleukin-10 is a useful salivary biomarker in periodontitis. 
Interleukin-17 
Since the discovery of the interleukin-17 secreting T-cell subset Th17, the dogma of the 
central importance of Th1 cytokines driving the “early”, stable and reversible gingivitis 
lesions versus Th2 cytokines driving the “later”, progressive periodontitis lesions has been 
challenged [34]. Interleukin-17 is produced by Th17 cells after activation of the adaptive 
immunity and serves to reinforce pro-inflammatory immune responses [35]. Although 
salivary interleukin-17 concentrations are minute in both periodontal health and disease 
[74], two studies comparing interleukin-17 in periodontal health and disease reported 
significantly lower concentrations in the latter [74, 77] (Table 2). However, salivary 
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interleukin-17 concentrations did not change after periodontal treatment [77].  In contrast, 
in a comparative analysis of different IL-17 isoforms, interleukin-17A, interleukin 17E and 
the interleukin-17A/F ratio was found to be significantly elevated in periodontitis patients 
[6].  It is currently unclear, therefore, whether interleukin-17 is a suitable periodontitis 
biomarker, although this seems unlikely given the very low concentrations present in saliva.  
Other immunoregulatory cytokines 
No differences between salivary concentrations of granulocyte-macrophage colony-
stimulating factor, interleukin-2, interleukin-5, interleukin-13 or interferon-γ between 
periodontal health and disease, or changes after periodontal treatment, have been reported 
(Table 2).  
Chemokines  
Chemokines target a wide range of immune cells, including neutrophils, lymphocytes and 
macrophages to facilitate their recruitment to the site of inflammation, and they are a key 
player in the pathogenesis of periodontitis [94, 107]. At least human 44 chemokines have 
thus far been identified and these are divided into 4 families on the basis of structural 
homology [107]. Chemokines such as macrophage inflammatory protein-1 (CCL3), 
interleukin-8  (CXCL8) and CXCL10 are produced by oral cells and tissues in response to pro-
inflammatory cytokines such as interleukin-1, tumour necrosis factor-α or interferon-γ, and 
bacterial products such as lipopolysaccharide or fimbriae [8, 79, 94]. Salivary concentrations 
of the neutrophil chemotactic factor interleukin-8 do not appear to be altered in 
periodontitis or following periodontitis treatment [81, 92, 103] (Table 2). Significantly higher 
salivary concentrations of the Th1-cell chemotactic factor macrophage inflammatory protein 
1 and the monocyte chemotactic protein-1 (also called CCL2) and have been found in 
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periodontitis compared to periodontal health [2, 40]. A decrease in salivary macrophage 
chemotactic protein-1 concentrations was found after periodontal treatment [40]; however, 
no change was observed for macrophage inflammatory protein-1 [92]. Currently, 
therefore, only macrophage chemotactic protein-1 seems to hold promise as a potential 
biomarker for periodontitis, but for the vast majority of chemokines there is no information 
available on salivary concentrations in periodontitis. 
Cytokines involved in bone cell regulation 
The receptor activator of nuclear factor kappa-B ligand-osteoprotegerin system has been 
the focus of many recent investigations in periodontal research. Receptor activator of 
nuclear factor kappa-B ligand is mainly produced by osteoblasts, fibroblasts and activated T 
and B cells. When binding to its receptor on pre-osteoclasts, receptor activator of nuclear 
factor kappa-B ligand induces osteoclast differentiation and bone resorption [39]. The decoy 
receptor osteoprotegerin is largely produced by fibroblasts and, through binding of receptor 
activator of nuclear factor kappa-B ligand, inhibits osteoclastogenesis [9].  In addition to 
roles in bone metabolism, these cytokines influence immune responses, emphasising the 
emerging paradigm that these two systems share common regulatory factors [9, 39]. 
Generally, it appears that receptor activator of nuclear factor kappa-B ligand is upregulated 
and osteoprotegerin is downregulated in periodontal disease [11, 17]. However, the results 
of the analysis of salivary concentrations of osteoprotegerin and receptor activator of 
nuclear factor kappa-B ligand in periodontal health and disease are not consistent. Out of 
eight studies, only three [16, 99, 105] simultaneously measured salivary concentrations of 
osteoprotegerin and receptor activator of nuclear factor kappa-B ligand (Table 3). Two of 
these studies showed a significant increase in receptor activator of nuclear factor kappa-B 
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ligand concentrations in periodontitis compared to periodontal health, but, of these two 
studies only Tobon-Arroyave et al. [105] noted lower levels of osteoprotegerin in 
periodontitis. Only one other study [80] recorded lower osteoprotegerin concentrations in 
periodontal disease as compared to health (Table 3). Two studies have investigated post-
treatment salivary concentrations of osteoprotegerin and both found a significant reduction 
after periodontal treatment [54, 92]. Salivary concentrations of receptor activator of nuclear 
factor kappa-B ligand have not been investigated after periodontitis treatment to date. 
Osteoprotegerin and receptor activator of nuclear factor kappa-B ligand show great promise 
as biomarkers of rheumatoid arthritis [110]. However, salivary concentrations of both 
osteoprotegerin and receptor activator of nuclear factor kappa-B ligand are relatively small 
and results from studies of periodontal disease are inconsistent. More data are needed to 
judge if salivary levels of receptor activator of nuclear factor kappa-B ligand and 
osteoprotegerin are suitable periodontitis biomarkers. Calprotectin [80] may be elevated in 
periodontitis but these studies are yet to be independently replicated. 
Growth factors 
So-called growth factors have been regarded as multifunctional, being involved in several 
physiological processes such as tissue development, regeneration and wound healing. More 
recently, these molecules have been revealed to have more specific roles in immune 
responses and inflammatory diseases. The paradigm for this has been transforming growth 
factor- that has numerous clearly defined roles in immunoregulation including regulation 
of T-cell subsets [32]. Although elevated levels of transforming growth factor- and other 
growth factors have been reported in gingival crevicular fluid [37] there are only very limited 
similar studies of saliva (and no available data on salivary transforming growth factor- in 
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periodontitis). One exception is hepatocyte growth factor which has been shown to 
enhance the production of matrix metalloproteinases and stimulates processes of wound 
healing such as vascularisation and keratinocyte proliferation [28, 61] and, more recently, 
numerous roles in inflammation and immunity have been revealed [65]. In oral tissues, 
hepatocyte growth factor is produced by periodontal ligament cells and gingival fibroblasts 
[71] in response to pro-inflammatory cytokines such as interleukin-1, tumor necrosis factor-
α as well as prostaglandin E2 and bacterial lipoteichoic acid [70, 98]. It is suggested the 
hepatocyte growth factor may drive apical migration of epithelial cells in periodontitis [49, 
70, 71]. Cross-sectional studies investigating salivary concentrations of hepatocyte growth 
factor consistently report elevated concentrations in periodontal disease compared to 
periodontal health and 2 longitudinal studies provide further substantial evidence in 
support of the potential of hepatocyte growth factor as a biomarker for periodontitis (Table 
4).  
Adipokines 
Adipokines comprise over 600 biologically active molecules produced by adipose tissue 
which include a wide range of pro- and anti-inflammatory cytokines (interleukin-1, tumour 
necrosis factor-, interleukin-6, interleukin-10) , growth factors (such as vascular 
endothelial growth factor and transforming growth factor- hormones (leptin, 
adiponectin, visfatin, resistin) and chemokines (monocyte chemotactic protein-1, 
interleukin-8) [58]. These molecules have wide-ranging and overlapping roles in physiology 
and there is an increasing recognition of their importance in immune-regulation and 
inflammatory disease [25, 69]. Many of the aforementioned adipokines are also synthesised 
by other cell types and are considered in other sections of this review.  
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The archetypal adipocyte-derived adipokine is leptin, which has well-defined pro-
inflammatory functions and is one potential mediator linking metabolic disease with 
common co-morbidities such as periodontitis and rheumatoid arthritis [22, 69, 101]. 
However, although there is some information implicating leptin in the pathogenesis of 
periodontitis there have been no studies of salivary leptin levels. However, the adipokines 
visfatin and chemerin have been found in significantly higher salivary concentrations in 
periodontitis compared to periodontal health [75, 100] (Table 5). Interestingly, although 
there is little direct evidence for a role of these adipokines in periodontitis pathogenesis, 
they do have relevant biological immunoregulatory functions; for example, visfatin does 
induces tumour necrosis factor-α, interleukin-6 and interleukin-1β in monocytes and 
fibroblasts and also acts as a chemoattractant for monocytes and B-cells [14, 66] and 
chemerin acts as a chemoattractant for various immune cells such as macrophages, 
dendritic cells and NK cells during inflammation [118].  
 
Identification of cytokine biomarkers from proteomic analysis of saliva 
The majority of studies investigating possible biomarkers for periodontal disease have used 
a ‘candidate’ biomarker approach exploiting existing information about disease 
pathogenesis. However, the proteome of human saliva has been characterised and is 
providing information underpinning a global, unbiased analytical approach to biomarker 
identification, an endeavour enhanced by recent developments in protein separation and 
mass spectrometry [24, 90]. This approach has been exploited in the identification of 
biomarkers for oral diseases including Sjogren’s syndrome and oral cancer [45, 46]. 
Although such proteomic studies have identified elevated levels of two of the S100 family of 
calcium binding proteins (which have cytokine-like activity in the regulation of 
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inflammation) [55, 86, 116] problems of sensitivity, recovery and processivity likely explain 
the limited data from proteomic studies relating to low abundance proteins such as 
cytokines [102]. 
 
Cytokines as an element of biomarker signature analysis 
It is generally accepted that the immunopathogenesis of periodontal disease is driven by 
complex and dynamic networks of cytokine interactions, which exhibit considerable inter-
individual variation rather than being dominated by the action of individual cytokines [52, 
79]. However cross-sectional analysis of multiple cytokines has generally not revealed 
consistent evidence for a ‘biomarker signature’ (e.g. Table 2). Cytokines are present in 
significantly lower concentrations in saliva than other mediators, for example enzymes such 
as matrix metalloproteinases, and therefore subtle changes may not always be detected. 
Indeed there is some evidence that analytical techniques with greater sensitivity and linear 
range may unmask periodontitis-associated biomarkers not detected by conventional 
enzyme-linked immunosorbant assays, which are almost universally used in research in this 
field [21]. Nonetheless, there have been some encouraging recent studies, which suggest 
that simultaneous analysis of a combination of interleukin-1, interleukin-6 and matrix 
metalloproteinase-8 strongly distinguished periodontitis patients from healthy individuals 
[29]. Also, differences in periodontal disease severity were efficiently detected by a 
combination of matrix metalloproteinase-8, matrix metalloproteinase-9, osteoprotegerin 
and calprotectin assays coupled with quantification of the periodontal pathogens 
Porphyromonas gingivalis and Treponema denticola in dental plaque [80]. Further studies 
revealed the combined levels of plaque bacterial biomarkers and salivary mediators (matrix 
metalloproteinase-8, matrix metalloproteinase-9, osteoprotegerin and interleukin-1) 
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successfully predicted progression of periodontal disease for the majority of patients 
studied [54].  
The intriguing concept that the biomarker tests required to screen for disease 
susceptibility and those which will be useful for monitoring response to therapy will be 
different has been raised, although this remains to be systematically investigated [108]. 
There is a wide variety of multiplex analysis platforms available but, unlike the popular 
sandwich enzyme-linked immunosorbant assays, no one multiplex approach has been 
universally adopted.  Indeed, concerns about imprecision and analyte recovery for some of 
these platforms have been highlighted and careful comparison with ‘gold standard’ ELISA 
methods is recommended before multiplex approaches are used in quantitative analysis of 
salivary mediators [15]. It is likely that many of these techniques are semi-quantitative at 
best and might only be considered of use for biomarker discovery.  
The effect of systemic diseases on salivary cytokine concentrations 
Few studies have investigated the impact of systemic diseases on salivary cytokines in 
periodontitis and none have been designed specifically with this aim in mind. Therefore, one 
has to be cautious when drawing conclusions from the presented study results.  Reports on 
salivary interleukin-1β concentrations in heart disease, hypertension, diabetes, 
inflammatory bowel disease or rheumatoid arthritis show no significant differences 
between patients and systemically healthy controls [64, 81, 117] even though oral health 
status was not always considered in the analysis [81]. A comparable theme can be seen for 
salivary interleukin-6 and tumour necrosis factor-α; concentrations of both do not appear to 
be affected by systemic conditions [3, 23, 64, 81, 96]. An investigation of the salivary 
concentrations of interleukin-1 receptor antagonist in diabetes revealed lower 
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concentrations in patients with periodontal disease as compared to those with periodontal 
health [19]. Since a non-diabetic control group was not included in this study, it is not 
possible to estimate whether local or systemic conditions influenced the levels of salivary 
interleukin-1 receptor antagonist.  Inflammatory bowel disease was associated with higher 
salivary interleukin-8 concentrations in one study, however since oral health status was not 
considered, it is not possible to evaluate local or systemic effects independently [81]. 
Similarly, an increase in salivary monocyte chemoattractant protein-1 concentrations in 
Sjögren's syndrome cannot be accounted for without evaluation of oral health [43]. The 
same study also investigated salivary macrophage inhibitory protein-1α concentrations and 
found no differences between patients with Sjögren's syndrome and systemically healthy 
controls [43].   
The effect of smoking on salivary cytokine concentrations 
Smoking is an established risk factor for periodontal disease [106] and it is reasonable to 
hypothesise that smoking may influence salivary cytokine levels.  Salivary concentrations of 
cytokines such as interleukin-1β and interleukin-6 do not appear to be affected by smoking 
although the concentrations of other salivary proteins were lower in smokers [51, 68, 81, 
82]. However, decreased concentrations of interleukin-8 in smokers compared to non-
smokers have been noted [81, 82]. One study found no association between receptor 
activator of nuclear factor kappa-B ligand or osteoprotegerin concentrations and smoking 
[105]. However, in contrast, higher receptor activator of nuclear factor kappa-B ligand and 
lower osteoprotegerin concentrations in the saliva of smokers with periodontitis compared 
to non-smokers with periodontitis have been reported [16]. Significantly elevated levels of 
hepatocyte growth factor were found in smokers with periodontitis as compared to non-
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smokers with periodontitis [4]. Considering the available data, it appears that smoking only 
has a limited impact on salivary cytokine concentrations. However, more research, which 
specifically aims to evaluate these relationships, is needed to come to firm conclusions.  
Concluding remarks 
The present review demonstrates that saliva is a valid local source for investigating 
periodontal cytokines, with many advantages over other sources such as gingival crevicular 
fluid. Care has to be taken when considering which methodology to choose for analysis; 
thus, not all commercial manufacturers of enzyme-linked immunosorbant assay kits provide 
quality control data for use with saliva samples and the utility of multiplex analysis remains 
somewhat uncertain. Also, despite the fact that it is established that cytokines are elements 
of complex and dynamic networks [93], precise interpretation of quantitative data above 
and beyond correlation analyses remains challenging.  
The majority of studies of salivary cytokines in periodontitis have either not yielded 
evidence for disease associations, or have yielded inconsistent results or positive 
correlations, which remain to be substantially replicated in independent studies. 
Nevertheless, current evidence suggests that of the molecules with cytokine-like activity 
studied thus far, interleukin-1β and hepatocyte growth factor are the most robust salivary 
biomarkers for periodontal disease. High quality research designs specifically targeting 
sensitivity and specificity and confounding factors such as smoking and systemic diseases 
should be the next step in salivary periodontitis biomarker research. This would help to 
evaluate if the biomarker knowledge can be implemented in a diagnostic test to detect 
periodontitis (or risk thereof) before periodontal tissue breakdown occurs.  Although there 
is much interest in developing ‘chairside’ tests for salivary mediators using novel 
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technologies, it is critical that such research is supported by substantial laboratory and 
clinical data confirming the clinical utility of individual candidate biomarkers. 
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Table 1. Studies of IL-1 family cytokines as candidate salivary biomarkers for periodontitis. 
 
Reference Study Type Patient groups IL-1 cytokine Principal findings 
[63] Case-control, 
cross-sectional 
28 periodontitis 
patients; 29 healthy 
controls 
IL-1 Significantly higher levels in periodontitis 
group (mean ± SD; 753.7 ± 1022.4 pg/ml) 
as compared to controls (212.8 ± 167.4 
pg/ml); significant positive correlation 
with bleeding on probing and clinical 
attachment loss measurements. 
[21]  Case-control, 
cross-sectional 
10 periodontitis 
patients; 9 healthy 
controls 
IL-1 No significant difference between groups. 
[67]  Cross-sectional 
with no controls 
98 periodontitis patients IL-1 Positive association between levels of IL-
1β and alveolar bone loss. 
[89]  Case-control, 
longitudinal 
study 
40 periodontitis patients 
with bone loss after 5 
years; 40 controls with 
no bone loss 
IL-1 Positive association with IL-1β and extent 
of alveolar bone loss over a 5-year 
period. 
[104]  Case-control, 
cross-sectional 
28 periodontitis 
patients; 29 healthy 
controls 
IL-1 Significantly higher levels in periodontitis 
group as compared to controls. 
[103]  Case-control, 
cross-sectional 
74 periodontitis 
patients; 44 healthy 
controls 
IL-1 No significant difference between groups 
[31]  Case-control, 
longitudinal 
study 
8 localised aggressive 
periodontitis patients 
with Aggregatibacter 
actinomycetemcomitans, 
IL-1, IL-1 IL-1β elevated in children who developed 
bone loss over a 2-3 year period 
compared to those who remained 
healthy. 
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20 healthy controls with 
A. 
actinomycetemcomitans 
and 20 healthy controls 
without A. 
actinomycetemcomitans 
[41]  Case-control, 
cross-sectional 
84 periodontitis 
patients; 81 healthy 
controls 
IL-1 Significantly higher levels in periodontitis 
group (Mean ± SD; 665.7 ± 267.5 pg/ml) 
as compared to controls (467.8 ± 279.8 
pg/ml). 
[80]  Case-control, 
cross-sectional 
49 periodontitis 
patients; 32 gingivitis 
patients; 18 healthy 
controls 
IL-1 No significant difference between groups. 
[64]  Case-control, 
cross-sectional 
35 periodontitis 
patients; 35 healthy 
controls 
IL-1 Significantly higher levels in periodontitis 
group as compared to controls (mean; 
33.11 pg/ml). Precise values for IL-
the periodontitis group not presented. 
[74]  Case-control, 
cross-sectional 
21 healthy adults;  52 
chronic periodontitis 
patients 
IL-18 Significantly increased concentration of 
IL-18 in periodontitis (mean ± SD; 275.05 
± 289.46 pg/ml) as compared to controls 
(143.71 ± 103.68 pg/ml). Significant 
positive correlation of IL-18 levels with 
bleeding on probing measurements. 
[50] Case-control, 
longitudinal 
study 
28 periodontitis 
patients; 24 healthy 
controls. Patients 
monitored 1 month after 
treatment (oral health 
instruction, scaling and 
IL-1 Significantly higher levels in periodontitis 
group (mean ± SD; 1312.75 ± 691.22 
pg/ml) as compared to controls (161.51 ± 
149.6 pg/ml). Significant positive 
correlation of IL-1
on probing, gingival index and plaque 
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root planning). index measurements.  Levels of IL-
in volunteers with moderate to severe 
periodontitis. 
[54] Case-control, 
longitudinal 
study 
17 moderate to severe 
periodontitis patients; 
24 mild periodontitis 
patients, 23 gingivitis 
patients; 15 healthy 
controls 
IL-1 Disease monitoring over 6 months (no 
treatment) then 6 months during which 
time treatment (oral health instruction, 
scaling and root planing as appropriate) 
was provided. No changes during 
monitoring phase but levels of IL-
in volunteers with moderate to severe 
periodontitis. 
 
[117]  Cross-sectional 
with no controls 
192 subjects with and 
without tye-2 diabetes 
mellitus 
IL-1 Levels correlate with clinical parameters 
of periodontal disease. 
[92]  Longitudinal 68 periodontitis 
patients. 35 patients 
undergoing both scaling 
and root-planing and 
oral hygiene instruction 
as compared to 33 
patients having oral 
hygiene instruction 
alone 
IL-1  IL-
received both scaling and root planing 
and oral hygiene instruction.  
[18]  Case-control, 
cross-sectional 
25 healthy adults; 32 
chronic periodontitis 
patients 
IL-33 No significant difference in IL-33 levels 
between groups. 
[82] Case-control, 49 severe periodontitis IL-1 Significantly higher levels in severe 
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cross-sectional patients; 89 mild 
periodontitis patients; 
303 healthy controls 
periodontitis group (mean ± SD; 144 ± 
220 pg/ml) and mild periodontitis (82 ± 
109 pg/ml)  as compared to controls (61 
± 87pg/ml). Significant positive 
correlation with bleeding on probing. No 
differences between smokers or ex-
smokers. 
[29] Case-control, 
cross-sectional 
30 healthy adults; 50 
severe periodontitis 
patients 
IL-1 Significantly higher levels in periodontitis 
group (mean ± SD; 90.94 ± 85.22pg/ml) 
as compared to controls (7.24 ± 7.69 
pg/ml). 
 
 
 
 
[87]  Cross-sectional 
with no controls 
340 no to mild 
periodontitis; 123 
moderate to severe 
periodontitis; 30 
edentulous 
IL-1 Levels significantly associated with all 
periodontitis parameters, presence of 
coronary artery disease and diabetes (but 
not smoking or ex smokers). Significantly 
lower levels in edentulous patients. 
 
IL-1, interleukin-1; IL-1interleukin-1; IL-18, interleukin-18; IL-33, interleukin-33.  
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Table 2. Studies of  immunoregulatory cytokines as candidate salivary biomarkers for periodontitis. 
 
Reference Study type Patient groups Cytokines  Principal findings 
[111] Cross-sectional 
with no controls 
30 moderate 
periodontitis patients 
and 9 severe 
periodontitis patients. 
Both groups were HIV+ 
IL-2, IL-4, IL-
10, IL-12, 
IFN- 
No significant differences between groups 
for any cytokine. 
[5] Cross-sectional, 
case-control  
10 periodontitis 
patients; 14 healthy 
controls 
TNF- TNF-not detected.  
[67]  Longitudinal  98 periodontitis patients IL-6 No association with alveolar bone loss. 
[89]  Longitudinal, 
case-control 
40 periodontitis patients 
with bone loss after 5 
years; 40 controls with 
no bone loss 
IFN-TNF-
IL-4, IL-6, 
IL-8 
No association with alveolar bone loss. 
[33]  Cross-sectional, 
case-control 
35 periodontitis 
patients; 39 healthy 
controls 
TNF- Significantly higher levels in periodontitis 
group (mean ± SEM; 4.33 ± 0.73 pg/ml) as 
compared to controls (2.03 ± 0.49 pg/ml). 
[31]  Longitudinal, 
case-control 
8 localised aggressive 
periodontitis patients 
with A. 
actinomycetemcomitans, 
20 healthy controls with 
A. 
actinomycetemcomitans 
and 20 healthy controls 
without A. 
21 cytokines 
including IL-
2, IL-3, IL-4, 
IL-5, IL-6, IL-
8, IL-9, IL-10, 
IL-12, IL-13, 
IL-17, 
RANTES, 
MCP-1, IFN-
MIP-1 elevated in children who 
developed bone loss compared to those 
who remained healthy. 
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actinomycetemcomitans 
Screening at 6 month 
intervals for 2-3 years 
TNF-
GM-CSF 
[41]  Cross-sectional, 
case-control 
84 periodontitis 
patients; 81 healthy 
controls 
 
IL-6; TNF- No significant differences between groups 
for either cytokine. 
[103] Cross-sectional, 
case-control 
74 periodontitis 
patients; 44 healthy 
controls 
GM-CSF; IL-
2; IL-4; IL-5; 
IL-6; IL-8; IL-
10; IFN-
TNF- 
No significant differences between groups 
for any cytokine. Significant negative 
correlation between IL-10 levels and 
bleeding on probing measurements. 
Significantly positive correlation between 
IL-8 and bleeding on probing 
measurements. 
[80]  Cross-sectional, 
case-control 
49 periodontitis 
patients; 32 gingivitis 
patients; 18 healthy 
controls 
IL-2, IL-4, IL-
5, IL-6, IL-10, 
IL-13, TNF-
 IFN- 
IL-5 and IFN-
differences between groups for the other 
cytokines. 
[23]  Cross-sectional, 
case-control 
24 periodontitis 
patients; 22 healthy 
controls 
IL-6 Significantly higher levels in periodontitis 
group as compared to controls. Values for 
IL-6 concentrations not presented. 
[74]  Cross-sectional, 
case-control 
21 healthy adults; 52 
chronic periodontitis 
patients 
IL-17 Significantly lower levels of IL-17 in 
periodontitis group as compared to 
controls. 
[64]  Cross-sectional, 
case-control 
35 periodontitis 
patients; 35 healthy 
controls 
TNF- No significant differences between groups. 
[92]  Longitudinal 68 periodontitis 
patients. 35 patients 
undergoing both scaling 
TNF- IL-8, 
MIP-1 
TNF-
groups, MIP-
compared to non-responders. 
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and root-planing and 
oral hygiene instruction 
as compared to 33 
patients having oral 
hygiene instruction 
alone. 
 
 
[2] Cross-sectional, 
case-control 
70 periodontitis 
patients; 40 healthy 
controls 
MIP-1  
 
Significantly higher levels of MIP-1 in 
periodontitis group as compared to 
controls. No values for MIP-1 levels 
presented. Significantly positive 
correlation between MIP-1 levels and 
both bleeding on probing and clinical 
attachment loss measurements. 
[77] Longitudinal 
study, cross-
sectional 
20 periodontitis 
patients; 20 healthy 
controls. Screening  6 
weeks after scaling and 
root-planing. 
IL-4, IL-6, IL-
10, IL-17 
Significantly higher levels of IL-4, IL-6, and 
significantly lower levels of IL-10 and IL-17 
in periodontitis group as compared to 
controls. IL-4 levels reduced to those of 
healthy volunteers 6 weeks after 
treatment. Cytokine concentrations not 
presented. 
[82]  Cross-sectional, 
case-control 
49 severe periodontitis 
patients; 89 
periodontitis patients; 
303 healthy controls 
IL-6, IL-8 No significant differences between groups. 
Significantly positive correlation between 
IL-8 and bleeding on probing 
measurements.  
[29]  Cross-sectional, 
case-control 
30 healthy adults; 50 
severe periodontitis 
patients 
TNF-IL-6, 
IFN- 
Significantly higher levels of IL-6 in 
periodontitis group (mean ± SD; 35.57 ± 
48.17 pg/ml) as compared to controls 
(3.30 ± 2.32 pg/ml); significantly lower 
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levels of IFN-in periodontitis group (3.19 
± 2.29 pg/ml) as compared to controls 
(27.65 ± 48.29 pg/ml). 
[40]  Cross-sectional, 
longitudinal 
30  periodontitis 
patients; 15 healthy 
controls. Screening 6 
weeks after scaling and 
root-planing. 
 
 
 
MCP-1 Significantly higher levels of MCP-1 in 
periodontitis group as compared to 
controls.  Values for MCP-1 concentrations 
not presented. 
[6]  Cross-sectional, 
Case-control 
97 periodontitis 
patients; 77 healthy 
controls 
IL-17A, IL-
17E, IL-17F 
IL-17A, IL-17 E and IL-17A/F ratio 
significantly elevated in periodontitis 
patients and positively correlated with 
various clinical parameters of 
periodontitis. 
 
GM-CSF, granulocyte macrophage-colony stimulating factor; IFN-, interferon-; IFN-, interferon-; IL-2, interleukin-2; IL-2, interleukin-3; IL-3, 
interleukin-4; IL-4, interleukin-4; IL-5, interleukin-5; IL-6, interleukin-6; IL-8, interleukin-8; IL-9, interleukin-9I; IL-10, interleukin-10; ;  IL-12, 
interleukin-12; ;  IL-13, interleukin-13; ;  IL-17, interleukin-17; RANTES, regulated on activation, normal T expressed and secreted; MCP-1, 
monocyte chemoattractant protein-1; MIP-1, macrophage inflammatory protein1
and secreted; TNF-, tumor necrosis factor-.   
40 
 
Table 3.  Studies of bone regulating cytokines as candidate salivary biomarkers for periodontitis. 
 
Reference Study type Patient groups Cytokines 
analysed 
Principal findings 
[63]  Cross sectional, 
case control 
28 periodontitis 
patients; 29 healthy 
controls 
OPG No significant difference between 
groups. 
[16]  Cross sectional 67 untreated chronic 
periodontitis patients; 
44 chronic 
periodontitis patients 
on maintenance 
therapy  
OPG, RANKL OPG levels correlated with clinical 
measures of periodontitis.  
[33]  Cross sectional, 
case control 
21 periodontitis 
patients; 21 healthy 
controls 
RANKL Only detected in a minority of subjects 
and no significant difference between 
groups. 
[80]  Cross sectional, 
case control 
21 moderate-severe 
periodontitis patients; 
28 mild periodontitis 
patients; 32 gingivitis 
patients; 18 healthy 
controls 
OPG, 
calprotectin 
 
Significantly lower levels of both 
cytokines in periodontitis (mild and 
severe) as compared to controls 
(gingivitis and healthy). OPG levels 
were (median, range): moderate-
severe periodontitis 1.9 pg/ml (0.2-10); 
mild periodontitis: 1.6 pg/ml; (0.5-
11.8); gingivitis: 2.7 pg/ml (1.2-6.2); 
healthy: 2.3 pg/ml (1.4-6.6).  
Calprotectin levels were moderate-
severe periodontitis 5.4 pg/ml (1.7-
97.6); mild periodontitis: 4.3 pg/ml (0-
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17.8); gingivitis: 3.5 pg/ml (0-24.6); 
healthy: 3.0 pg/ml (1.3-10).   
[23]  Cross sectional, 
case control 
24 periodontitis 
patients; 22 healthy 
controls 
 
OPG No significant difference between 
groups 
[54] Longitudinal, case 
control 
17 moderate to severe  
periodontitis patients; 
24 mild periodontitis 
patients, 23 gingivitis 
patients; 15 healthy 
controls 
OPG, 
calprotectin,  
No changes during monitoring phase 
but levels of OPG declined significantly 
after 6 months treatment in volunteers 
with moderate to severe periodontitis. 
Data presented in graphical form only. 
[92]   68 periodontitis 
patients: 35 patients 
undergoing both 
scaling and root  
planning and oral 
hygiene instruction as 
compared to 33  
patients having oral 
hygiene instruction 
alone. 
OPG OPG levels declined in both treatment 
groups. Data presented in graphical 
form only. 
[105]  Cross sectional, 
case control 
97 periodontitis 
patients; 43 healthy 
controls 
OPG, RANKL Significantly higher levels of RANKL and 
significantly lower levels of OPG in 
periodontitis group as compared to 
controls. Levels are (median, inter-
quartile range): OPG: periodontitis 
95.2 pg/ml (49.8-145.2); healthy 131.6 
pg/ml (82.2-202.4); RANKL: 
periodontitis 6.0 pg/ml (2.7-11.1); 
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healthy 4.0 pg/ml (2.4-6.6). 
[99]  Cross sectional, 
case control 
25 chronic 
periodontitis patients; 
25 healthy controls 
OPG, RANKL Significantly higher levels of RANKL in 
the periodontitis group  (266 ± 48 
pg/ml; median ± interquartile range) as 
compared to controls (207 ± 83 pg/ml). 
No significant difference in OPG levels 
between groups. 
 
OPG, osteoprotegerin; RANKL, receptor activator of nuclear factor-kappaB ligand. 
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Table 4. Studies of growth factors as candidate salivary biomarkers for periodontitis. 
 
Reference Study type Patient groups Growth factor Salivary growth factor levels 
[13]  Cross sectional, 
case control 
32 periodontitis 
patients and 12 
healthy controls  
VEGF Significantly higher levels in periodontitis 
group as compared to controls.  Data 
presented in graphical form only. 
[89]  Longitudinal, case 
control 
40 periodontitis 
patients with bone 
loss after 5 years; 
40 controls with 
no bone loss 
HGF  Positive association with HGF and extent of 
alveolar bone loss over a 5 year period. 
[113] Cross sectional, 
case control 
26 periodontitis 
patients; 20 
healthy controls 
HGF Significantly higher levels in periodontitis 
group (Mean, range: 1.87 ng/ml; 0.06-5.38) 
as compared to controls (0.68 ± ng/ml; 0-
7.33). HGF levels correlated with gingival 
index, plaque index and papillary bleeding 
index.  
[85] Cross sectional, 
case control 
12 severe 
periodontitis 
patients; 12 
moderate 
periodontitis; 12 
healthy controls 
HGF Significantly higher levels in severe 
periodontitis group  (mean ± SD; 3430.8 ± 
1640.2) and moderate periodontitis group 
(1878.99 ± 1713.54 pg/ml) as compared to 
controls (443.82 ± 295.14 pg/ml). 
[114] Cross sectional, 
case control 
26 periodontitis 
patients; 20 
healthy controls 
HGF Significantly higher levels in periodontitis 
group as compared to controls. Data 
presented previously (see   above) 
 
HGF, hepatocyte growth factor; VEGF, vascular endothelial growth factor.  
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Table 5. Studies of adipokines as candidate salivary biomarkers for periodontitis. 
 
Reference Study type Patient groups Adipokine Principal findings 
[75] Cross sectional, 
case-control 
25 patients with chronic 
periodontitis, 24 
patients with gingivitis, 
25 healthy controls 
Chemerin, 
visfatin, 
progranulin 
and TNF- 
Chemerin was significantly elevated in the 
periodontitis group (median, range: 
0.084ng/ml, 0.063-0.105) but not the 
gingivitis group (0.042ng/ml, 0.042-0.063) as 
compared to controls (0.042ng/ml, 0.023-
0.063). Visfatin was significantly elevated in 
both the periodontitis group (589 ng/ml, 
302-1195) and the gingivitis group (791 
ng/ml, 267-1127) as compared to controls 
(267 ng/ml (125-616).  Levels of chemerin 
but not visfatin correlated with clinical 
attachment loss measurements. 
[100] Cross sectional, 
case-control 
20 patients with chronic 
periodontitis, 20 healthy 
controls 
Visfatin Visfatin significantly elevated in periodontitis 
(mean ± SD: 33.43 ± 15.72 ng/ml) as 
compared to controls (23.38 ± 7.58 ng/ml). 
 
TNF-, tumor necrosis factor-.
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